Implantica completes Human Factors Validation Study for RefluxStop™ as part of the US FDA Premarket Approval Process

Implantica Liechtenstein

for further information.

About RefluxStop™

RefluxStop™ is a new innovative treatment that has the potential to spur a paradigm shift in anti-reflux surgery. It's unique mechanism of action differentiates it from standard of care and current surgical solutions. Longer established surgical options for GERD involve encircling the food passageway to support the lower esophageal sphincter's closing mechanism and are commonly associated with side effects such as swallowing difficulties, pain when swallowing and inability to belch and/or vomit.

In contrast, the RefluxStop device treats the cause of acid reflux without encircling and putting pressure on the food passageway. It restores and maintains the lower esophageal sphincter in its original, natural position.

The RefluxStop™ mechanism of action is focused on reconstructing all three components of the anti-reflux barrier, that if compromised could possibly result in acid reflux. It restores and supports the natural anatomical physiology of the body allowing the body to itself solve the problem with acid reflux.

Newsroom
https://www.implantica.com/media/media-kit

Community
https://ch.linkedin.com/company/implantica
https://www.twitter.com/implantica

Media Contact:
Implantica AG
Juanita Eberhart, VP Marketing & Advocacy
M: [phone]
[e-mail] 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/implantica/r/implantica-completes-human-factors-validation-study-for-refluxstop--as-part-of-the-us-fda-premarket-,c3952062

The following files are available for download:

https://mb.cision.com/Main/19732/3952062/2695354.pdf

Implantica completes Human Factors Validation Study for RefluxStopâ„¢ as part of the US FDA Premarket Approval Process

https://news.cision.com/implantica/i/logo-transparent-1-8,c3283071

logo transparent 1 8

https://news.cision.com/implantica/i/refluxstop,c3283072

REFLUXSTOP

 

View original content:https://www.prnewswire.co.uk/news-releases/implantica-completes-human-factors-validation-study-for-refluxstop-as-part-of-the-us-fda-premarket-approval-process-302099147.html